13F Holdings
中文EN

CGEN COMPUGEN LTD Annual reports only

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1119774 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY161.1%
TTM net income YoY348.4%
TTM EPS YoY337.5%
Revenue 3-yr CAGR113.3%
Net income 3-yr CAGR—

Margins

Gross margin87.3%
Operating margin43.1%
Net margin48.6%
FCF margin43.1%
EBITDA margin43.7%

Returns

ROE44.8%
ROA26.0%
ROIC (approx.)128.1%
Asset turnover0.54x

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio6.56x
Interest coverage1,118.79x

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio2.7%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$72.76M$27.86M$33.46M$7.50M$6.00M
Cost of revenue$9.25M$7.93M$2.00M$975,000$680,000
Gross profit$63.51M$19.93M$31.45M$6.53M$5.32M
R&D expense$22.76M$24.81M$34.47M$30.65M$28.69M
SG&A expense$8.89M$9.44M$9.73M$10.32M$10.86M
Operating income$31.33M-$14.89M-$12.99M-$35.37M-$35.07M
Interest expense$28,000$34,000$31,000$27,000$25,000
Pretax income$35.40M-$9.71M-$9.78M-$33.64M-$34.20M
Income tax$54,000$4.52M$8.97M$58,000$0
Net income$35.34M-$14.23M-$18.75M-$33.69M-$34.20M
EBITDA$31.80M-$14.40M-$12.52M-$34.89M-$34.61M
EPS (basic)0.38-0.16-0.21-0.39-0.41
EPS (diluted)0.38-0.16-0.21-0.39-0.41
Weighted avg. shares (diluted)93.82M89.53M87.63M86.56M84.20M
Balance sheet
Cash & equivalents$90.60M$18.23M$13.89M$11.42M$8.51M
Short-term investments$9.28M$23.63M$11.74M$0—
Receivables—$0$61.00M$0—
Current assets$148.02M$106.00M$114.58M$86.12M$123.22M
PP&E, net$681,000$852,000$1.22M$1.53M$1.66M
Total assets$156.57M$115.00M$121.33M$94.18M$132.16M
Current liabilities$22.57M$20.16M$26.27M$11.92M$17.10M
Total liabilities$53.84M$60.08M$55.77M$16.50M$25.47M
Shareholders' equity$102.73M$54.91M$65.56M$77.68M$106.69M
Shares outstanding94.55M89.54M89.24M86.62M86.43M
Cash flow statement
Operating cash flow$31.63M$49.60M-$35.89M-$34.11M-$22.69M
Capital expenditure$306,000$118,000$172,000$477,000$292,000
Free cash flow$31.33M$49.49M-$36.06M-$34.59M-$22.98M
Investing cash flow$30.00M-$46.25M$35.51M$37.06M$6.62M
Financing cash flow$10.60M$554,000$3.08M$353,000$16.84M
Depreciation & amortization$475,000$486,000$476,000$482,000$461,000
Stock-based compensation$1.88M$3.02M$3.55M$4.33M$4.28M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.